Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent and fast acting antimalarials; but they have a short half-life and need to be combined with partner drugs with a longer half...
Main Author: | Christian Nsanzabana |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Tropical Medicine and Infectious Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2414-6366/4/1/26 |
Similar Items
-
Clinical Pharmacology of the Antimalarial Artemisinin-Based Combination and other Artemisinins in Children
by: Gian Maria Pacifici
Published: (2018-07-01) -
Artemisia scoparia – A new source of artemisinin
by: Aditi Singh, et al.
Published: (2010-06-01) -
Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape
by: Christian Nsanzabana, et al.
Published: (2018-02-01) -
Artemisinin
Published: (2014-07-01) -
Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria
by: Jamsen Kris M, et al.
Published: (2012-07-01)